Paper36966349
Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.
Kal Omar R and 2 others. Trials, 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study. Papers, record 36966349. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966349
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Melatonin | Major topic |
| Melanoma | Major topic |
| Skin Neoplasms | Major topic |
| Uveal Neoplasms | Major topic |
| Adult | |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Clinical Trials, Phase III as Topic | |
| Uveal Melanoma |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| SLS-971390 | The Swedish Society of Medicine | PubMed | ||
| ME2019-0036 | The Royal Swedish Academy of Sciences | PubMed | ||
| 20 0798 Fk | Cancerfonden | PubMed | ||
| RS-2019-1138 | Region Stockholm | PubMed | ||
| 2022-05-02 | The Swedish Eye Foundation | PubMed | ||
| FS-2021-0010 | Karolinska Institutet | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05502900 | Adjuvant Melatonin for Uveal Melanoma | Background | Yes |
Source ClinicalTrials.gov
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28823399 | Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis. | Ophthalmology | 2018 | https://conductscience.org/library/papers/28823399 | PubMed |
| 2 | 17418968 | Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). | Int J Radiat Oncol Biol Phys | 2007 | https://conductscience.org/library/papers/17418968 | PubMed |
| 3 | 25813452 | American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture. | Ophthalmology | 2015 | https://conductscience.org/library/papers/25813452 | PubMed |
| 4 | 8570130 | Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. | Oncology | 1996 | https://conductscience.org/library/papers/8570130 | PubMed |
| 5 | 35413810 | The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35413810 | PubMed |
| 6 | 25058347 | Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. | Br J Cancer | 2014 | https://conductscience.org/library/papers/25058347 | PubMed |
| 7 | 9067962 | Melatonin inhibits growth of cultured human uveal melanoma cells. | Melanoma Res | 1997 | https://conductscience.org/library/papers/9067962 | PubMed |
| 8 | 32258021 | BAP1 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma. | Ocul Oncol Pathol | 2020 | https://conductscience.org/library/papers/32258021 | PubMed |
| 9 | 27822007 | Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973-2012). | Clin Ophthalmol | 2016 | https://conductscience.org/library/papers/27822007 | PubMed |
| 10 | 5067774 | Melatonin and parkinsonism. | JAMA | 1972 | https://conductscience.org/library/papers/5067774 | PubMed |
| 11 | 1531290 | A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. | Arch Ophthalmol | 1992 | https://conductscience.org/library/papers/1531290 | PubMed |
| 12 | 10928160 | A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. | Anticancer Res | 2000 | https://conductscience.org/library/papers/10928160 | PubMed |
| 13 | 16596311 | The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies. | Cancer Causes Control | 2006 | https://conductscience.org/library/papers/16596311 | PubMed |
| 14 | 20413675 | An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. | J Mol Diagn | 2010 | https://conductscience.org/library/papers/20413675 | PubMed |
| 15 | 30910871 | Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. | Br J Ophthalmol | 2020 | https://conductscience.org/library/papers/30910871 | PubMed |
| 16 | 18505083 | Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. | Anticancer Res | 2008 | https://conductscience.org/library/papers/18505083 | PubMed |
| 17 | 8989723 | Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. | J Pineal Res | 1996 | https://conductscience.org/library/papers/8989723 | PubMed |
| 18 | 7334363 | Effect of melatonin on experimental tumors under different photoperiods and times of administration. | J Neural Transm | 1981 | https://conductscience.org/library/papers/7334363 | PubMed |
| 19 | 31952224 | Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/31952224 | PubMed |
| 20 | 4028009 | Effect of melatonin on B16 melanoma growth in athymic mice. | Cancer Res | 1985 | https://conductscience.org/library/papers/4028009 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42065061 | Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies. | Oncol Res | 2026 | https://conductscience.org/library/papers/42065061 | PubMed |
| 41737289 | Current Therapies and Potential Strategies for Uveal Melanoma. | Drugs Drug Candidates | 2025 | https://conductscience.org/library/papers/41737289 | PubMed |
| 40305352 | Melatonin MT1 Receptor Expression in Luminal Invasive Ductal Breast Carcinoma in Postmenopausal Women. | Biomolecules | 2025 | https://conductscience.org/library/papers/40305352 | PubMed |
| 38911030 | The Role and Therapeutic Potential of Melatonin in Degenerative Fundus Diseases: Diabetes Retinopathy and Age-Related Macular Degeneration. | Drug Des Devel Ther | 2024 | https://conductscience.org/library/papers/38911030 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| BAP1 | 8314 | PubTator's text mining | https://conductscience.org/library/genes/8314 | NCBI Gene |
| CYP1A2 | 1544 | PubTator's text mining | https://conductscience.org/library/genes/1544 | NCBI Gene |
| GH1 | 2688 | PubTator's text mining | https://conductscience.org/library/genes/2688 | NCBI Gene |
| GOLGB1 | 2804 | PubTator's text mining | https://conductscience.org/library/genes/2804 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| MT1IP | 644314 | PubTator's text mining | https://conductscience.org/library/genes/644314 | NCBI Gene |
| MT2A | 4502 | PubTator's text mining | https://conductscience.org/library/genes/4502 | NCBI Gene |
| TENM1 | 10178 | PubTator's text mining | https://conductscience.org/library/genes/10178 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36966349
GET https://conductscience.org/api/papers/v1/36966349/references?page=2